{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:52:08Z","timestamp":1789908728439,"version":"4.0.1"},"reference-count":173,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2019.01327","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T10:59:38Z","timestamp":1560941978000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":102,"title":["Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections"],"prefix":"10.3389","volume":"10","author":[{"given":"Mohammad Amin","family":"Behzadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Leyva-Grado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/INF.0b013e31818ffd03","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children","volume":"28","author":"Abarca","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref2","article-title":"Therapeutic efficacy of JNJ-53718678, a RSV fusion inhibitor, in neonatal lambs","volume-title":"10th international respiratory syncytial virus symposium","author":"Ackermann","year":"2016"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12879-016-1492-4","article-title":"Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia","volume":"16","author":"Al Ghamdi","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fmicb.2016.00450","article-title":"Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections","volume":"7","author":"Alame","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e00694-18","DOI":"10.1128\/AAC.00694-18","article-title":"Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jinf.2017.06.002","article-title":"A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia","volume":"75","author":"Al-Tawfiq","year":"2017","journal-title":"J. Infect."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/14787210.2017.1271712","article-title":"Update on therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)","volume":"15","author":"Al-Tawfiq","year":"2017","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijid.2013.12.003","article-title":"Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study","volume":"20","author":"Al-Tawfiq","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.arbres.2016.07.004","article-title":"Anti-influenza treatment: drugs currently used and under development","volume":"53","author":"Amarelle","year":"2017","journal-title":"Arch. Bronconeumol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/TP.0000000000001928","article-title":"Sofosbuvir-based regimens in HIV\/HCV Coinfected patients after liver transplantation: results from the ANRS CO23 CUPILT study","volume":"102","author":"Antonini","year":"2018","journal-title":"Transplantation"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13063-017-2427-0","article-title":"Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial","volume":"19","author":"Arabi","year":"2018","journal-title":"Trials"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Arabi","year":"2015","journal-title":"Springerplus"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S1473-3099(13)70204-4","article-title":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study","volume":"13","author":"Assiri","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nchembio.1982","article-title":"Molecular mechanism of respiratory syncytial virus fusion inhibitors","volume":"12","author":"Battles","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S1473-3099(18)30002-1","article-title":"Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study","volume":"18","author":"Beigel","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/AAC.03947-14","article-title":"Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro","volume":"59","author":"Belardo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1086\/522609","article-title":"DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection","volume":"196","author":"Belser","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"20290","DOI":"10.2807\/ese.17.40.20290-en","article-title":"Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012","volume":"17","author":"Bermingham","year":"2012","journal-title":"Euro Surveill."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1073\/pnas.1017142108","article-title":"Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)","volume":"108","author":"Bonavia","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1021\/jm070143x","article-title":"Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure\u2212property relationship","volume":"50","author":"Bonfanti","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1021\/jm701284j","article-title":"Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)","volume":"51","author":"Bonfanti","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01720610-201210000-00005","article-title":"Respiratory tract infections: emerging viral pathogens","volume":"25","author":"Borchardt","year":"2012","journal-title":"JAAPA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.bmcl.2015.03.013","article-title":"Isosteric replacements of the carboxylic acid of drug candidate VX-787: effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors","volume":"25","author":"Boyd","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref25","article-title":"Middle East respiratory syndrome (MERS)","year":"2017"},{"key":"ref26","article-title":"Influenza antiviral medications: summary for clinicians","year":""},{"key":"ref27","article-title":"Respiratory syncytial virus (RSV)","year":""},{"key":"ref28","article-title":"Summary of the 107-2018 Influenza season","year":""},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1128\/AAC.04119-14","article-title":"Mechanism of action for respiratory syncytial virus inhibitor RSV604","volume":"59","author":"Challa","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3201\/eid2107.150178","article-title":"Absence of MERS-coronavirus in Bactrian camels, southern Mongolia, November 2014","volume":"21","author":"Chan","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1128\/AAC.00211-07","article-title":"RSV604, a novel inhibitor of respiratory syncytial virus replication","volume":"51","author":"Chapman","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","article-title":"Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond","volume":"155","author":"Chaudhuri","year":"2018","journal-title":"Antiviral Res."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-38919-1_1","article-title":"Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease","volume-title":"Challenges and opportunities for respiratory syncytial virus vaccines","author":"Collins","year":"2013"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3389\/fimmu.2018.01946","article-title":"Treating influenza infection, from now and into the future","volume":"9","author":"Davidson","year":"2018","journal-title":"Front. Immunol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40262-017-0564-y","article-title":"Pharmacokinetics of MHAA4549A, an anti-influenza A monoclonal antibody, in healthy subjects challenged with influenza A virus in a phase IIa randomized trial","volume":"57","author":"Deng","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref37","article-title":"Delivery of ALX-0171 by inhalation greatly reduces disease burden in a neonatal lamb RSV infection model","volume-title":"9th international respiratory syncytial virus symposium","author":"Detalle","year":"2014"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e1004995","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2\u2032-fluoro-4\u2032-chloromethyl-cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS Pathog."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/00006454-200008000-00032","article-title":"Therapy of respiratory syncytial virus infection","volume":"19","author":"Devincenzo","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus","volume":"107","author":"Devincenzo","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"Devincenzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/bs.aivir.2016.08.003","article-title":"Molecular basis of coronavirus virulence and vaccine development","volume":"96","author":"Enjuanes","year":"2016","journal-title":"Adv. Virus Res."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat. Med."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1513\/AnnalsATS.201311-405PS","article-title":"The global burden of respiratory disease","volume":"11","author":"Ferkol","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref50","article-title":"FDA approves new drug to treat influenza","year":"2018"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e9106","DOI":"10.1371\/journal.pone.0009106","article-title":"New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets","volume":"5","author":"Friesen","year":"2010","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/jp.2008.28","article-title":"Prevention of hospitalization due to respiratory syncytial virus: results from the palivizumab outcomes registry","volume":"28","author":"Frogel","year":"2008","journal-title":"J. Perinatol."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/jac\/dky462","article-title":"Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection","volume":"74","author":"Fukao","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healun.2015.08.012","article-title":"ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients","volume":"35","author":"Gottlieb","year":"2016","journal-title":"J. Heart Lung Transplant."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e01714","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref59","article-title":"Human antibodies to respiratory syncytial virus F protein and methods of use thereof","author":"Gurnett-Bander","year":"2016"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref61","first-page":"A4457","article-title":"A phase 2b, randomized, double-blind, placebo-controlled trial of Presatovir (GS-5806), a novel Oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults","volume-title":"C17. New insights in acute pulmonary infections","author":"Hanfelt-Goade","year":"2018"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.toxlet.2012.03.176","article-title":"ALX-0171 toxicity study in RSV-infected cotton rats: safety and therapeutic potential","volume":"211","author":"Hanton","year":"2012","journal-title":"Toxicol. Lett."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1086\/600108","article-title":"Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB\/c mice","volume":"200","author":"Haynes","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.09.014","article-title":"Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery","volume":"127","author":"Heylen","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1128\/JVI.02472-14","article-title":"Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis","volume":"89","author":"Hotard","year":"2015","journal-title":"J. Virol."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40262-017-0522-8","article-title":"Population pharmacokinetic modeling of JNJ-53718678, a novel fusion inhibitor for the treatment of respiratory syncytial virus: results from a phase I, double-blind, randomized, placebo-controlled first-in-human study in healthy adult subjects","volume":"56","author":"Huntjens","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.antiviral.2017.11.013","article-title":"Prevention and treatment of respiratory viral infections: presentations on antiviral, traditional therapies and host-directed interventions at the 5th ISIRV antiviral group conference. Meeting report","volume":"149","year":"2018","journal-title":"Antiviral Res."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccm.2016.11.008","article-title":"Antiviral treatments","volume":"38","author":"Ison","year":"2017","journal-title":"Clin. Chest Med."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"e0126959","DOI":"10.1371\/journal.pone.0126959","article-title":"Antiviral activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a non-human primate model","volume":"10","author":"Ispas","year":"2015","journal-title":"PLoS One"},{"key":"ref71","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw172.513","article-title":"Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (RSV): a placebo-controlled challenge study","volume-title":"Open forum infectious diseases","author":"Israel","year":"2016"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s11684-017-0596-6","article-title":"Human monoclonal antibodies as candidate therapeutics against emerging viruses","volume":"11","author":"Jin","year":"2017","journal-title":"Front. Med."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e1005318","DOI":"10.1371\/journal.ppat.1005318","article-title":"Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures","volume":"11","author":"Johnson","year":"2015","journal-title":"PLoS Pathog."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e00430-18","DOI":"10.1128\/mBio.01868-18","article-title":"Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors","volume":"9","author":"Jones","year":"2018","journal-title":"MBio"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"2040206618764483","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the treatment of respiratory RNA virus infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/17476348.2017.1338567","article-title":"Respiratory syncytial virus: prospects for new and emerging therapeutics","volume":"11","author":"Jorquera","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/cid\/ciu635","article-title":"Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States","volume":"59","author":"Kapoor","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3851\/IMP2792","article-title":"Ribavirin and interferon-alpha2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases","volume":"20","author":"Khalid","year":"2015","journal-title":"Antivir. Ther."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e2015033","DOI":"10.4178\/epih\/e2015033","article-title":"2015 MERS outbreak in Korea: hospital-to-hospital transmission","volume":"37","author":"Ki","year":"2015","journal-title":"Epidemiol. Health"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/irv.12503","article-title":"The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin","volume":"11","author":"Kim","year":"2017","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/v10020072","article-title":"Favipiravir and ribavirin inhibit replication of Asian and African strains of Zika virus in different cell models","volume":"10","author":"Kim","year":"2018","journal-title":"Viruses"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3851\/IMP3002","article-title":"Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir. Ther."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1086\/648378","article-title":"Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir","volume":"200","author":"Koudstaal","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1128\/AAC.00607-16","article-title":"Two phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza A virus monoclonal antibody, MHAA4549A, in healthy volunteers","volume":"60","author":"Lim","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref87","article-title":"Compositions and methods for \u201cresistance-proof\u201d SiRNA therapeutics for influenza","author":"Lu","year":"2018"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"326ra321","DOI":"10.1126\/scitranslmed.aaf1061","article-title":"Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo","volume":"8","author":"Luke","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref89","first-page":"1630","article-title":"Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study","volume-title":"J. Med. Chem.","author":"Mackman","year":"2015"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/infdis\/jiu105","article-title":"An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality","volume":"210","author":"Marjuki","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/infdis\/jiu447","article-title":"Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan","volume":"211","author":"Marjuki","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref94","article-title":"A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of RSV604 in adults with respiratory syncytial virus infection following stem cell transplantation","volume-title":"Proceedings of the IXth international symposium on respiratory viral infections.","author":"Marty","year":"2007"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"e90383","DOI":"10.1371\/journal.pone.0090383","article-title":"Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production","volume":"9","author":"Matsushita","year":"2014","journal-title":"PLoS One"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"e01154-17","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model","volume":"61","author":"McBride","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref97","article-title":"Middle east respiratory syndrome coronavirus: Treatment and prevention","author":"McIntosh","year":"2017"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1056\/NEJMc1308698","article-title":"Middle East respiratory syndrome coronavirus infections in health care workers","volume":"369","author":"Memish","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1093\/jac\/dkw338","article-title":"A review of treatment modalities for Middle East respiratory syndrome","volume":"71","author":"Mo","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S2055-6640(20)30696-8","article-title":"Treatment strategies for Middle East respiratory syndrome coronavirus","volume":"2","author":"Modjarrad","year":"2016","journal-title":"J. Virus Erad."},{"key":"ref101","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1016\/j.ijid.2013.07.002","article-title":"Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV) \u2013 possible lessons from a systematic review of SARS-CoV therapy","volume":"17","author":"Momattin","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"ref102","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3181\/00379727-92-22538","article-title":"Recovery of cytopathogenic agent from chimpanzees with goryza","volume":"92","author":"Morris","year":"1956","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection","volume":"206","author":"Moss","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jiph.2017.08.009","article-title":"Current treatment options and the role of peptides as potential therapeutic components for Middle East respiratory syndrome (MERS): a review","volume":"11","author":"Mustafa","year":"2018","journal-title":"J. Infect. Public Health"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.chom.2013.06.004","article-title":"An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies","volume":"14","author":"Nakamura","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/S1473-3099(15)00247-9","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy native American infants: a phase 3 randomised double-blind placebo-controlled trial","volume":"15","author":"O\u2019brien","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref108","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jhin.2015.08.002","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): what lessons can we learn?","volume":"91","author":"Omrani","year":"2015","journal-title":"J. Hosp. Infect."},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1093\/gbe\/evx138","article-title":"The combined effect of oseltamivir and favipiravir on influenza A virus evolution","volume":"9","author":"Ormond","year":"2017","journal-title":"Genome Biol. Evol."},{"key":"ref110","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/zph.12435","article-title":"Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE","volume":"65","author":"Paden","year":"2018","journal-title":"Zoonoses Public Health"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/JVI.6.4.556-558.1970","article-title":"Quantitative determination of neuraminidase-active foci in cell monolayer cultures infected with influenza or Newcastle disease virus","volume":"6","author":"Palese","year":"1970","journal-title":"J. Virol."},{"key":"ref112","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhin.2018.09.005","article-title":"Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers","volume":"101","author":"Park","year":"2019","journal-title":"J. Hosp. Infect."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"8738","DOI":"10.1073\/pnas.1510830112","article-title":"Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection","volume":"112","author":"Pascal","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/infdis\/jix292","article-title":"The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses","volume":"216","author":"Paules","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref115","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijid.2015.06.004","article-title":"Middle East respiratory syndrome \u2013 advancing the public health and research agenda on MERS \u2013 lessons from the South Korea outbreak","volume":"36","author":"Petersen","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref116","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.bbamem.2010.04.015","article-title":"Influenza M2 proton channels","volume":"1808","author":"Pielak","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","article-title":"Economic burden of seasonal influenza in the United States","volume":"36","author":"Putri","year":"2018","journal-title":"Vaccine"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/17476348.2017.1367288","article-title":"Middle East respiratory syndrome coronavirus: five years later","volume":"11","author":"Rabaan","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"ref119","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1099\/jmm.0.000565","article-title":"A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective","volume":"66","author":"Rabaan","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/17425250902988487","article-title":"Thiazolides: a new class of antiviral drugs","volume":"5","author":"Rossignol","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref121","doi-asserted-by":"publisher","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref122","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1128\/AAC.00643-10","article-title":"Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model","volume":"54","author":"Rouan","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref123","first-page":"9","article-title":"Discovery of JNJ-53718678, a potent inhibitor of RSV","volume-title":"9th international respiratory syncytial virus symposium","author":"Roymans","year":"2014"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1128\/AAC.00761-15","article-title":"GS-5806 inhibits pre-to postfusion conformational changes of the respiratory syncytial virus fusion protein","volume":"59","author":"Samuel","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref125","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1172\/JCI78450","article-title":"Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge","volume":"125","author":"Schickli","year":"2015","journal-title":"J. Clin. Invest."},{"key":"ref126","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature06531","article-title":"Structure and mechanism of the M2 proton channel of influenza A virus","volume":"451","author":"Schnell","year":"2008","journal-title":"Nature"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s41669-017-0042-3","article-title":"Assessing variation in the cost of palivizumab for respiratory syncytial virus prevention in preterm infants","volume":"2","author":"Shahabi","year":"2017","journal-title":"PharmacoEconomics-Open"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/jac\/dkv085","article-title":"IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study","volume":"70","author":"Shalhoub","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref129","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1021\/acsinfecdis.7b00142","article-title":"The next wave of influenza drugs","volume":"3","author":"Shaw","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref130","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref131","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv133.628","article-title":"Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: a new human monoclonal RSV-F antibody for RSV prevention","volume-title":"Open forum infectious diseases","author":"Sivapalasingam","year":"2015"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1128\/AAC.02556-13","article-title":"Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013","volume":"58","author":"Sleeman","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref133","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2016.10.009","article-title":"Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice","volume":"136","author":"Smee","year":"2016","journal-title":"Antiviral Res."},{"key":"ref134","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref135","doi-asserted-by":"publisher","first-page":"851","DOI":"10.4155\/fmc-2017-0217","article-title":"Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza A virus","volume":"10","author":"Stachulski","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref136","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/v5010211","article-title":"Respiratory syncytial virus entry inhibitors targeting the F protein","volume":"5","author":"Sun","year":"2013","journal-title":"Viruses"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir","volume":"132","author":"Takashita","year":"2016","journal-title":"Antiviral Res."},{"key":"ref138","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1128\/AAC.04836-14","article-title":"Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan","volume":"59","author":"Takashita","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref139","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.3389\/fmicb.2018.03026","article-title":"Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor Baloxavir Marboxil","volume":"9","author":"Takashita","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10096-018-3289-4","article-title":"Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches","volume":"37","author":"Taleb","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref141","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antiviral Res."},{"key":"ref142","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.chom.2014.04.009","article-title":"Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure","volume":"15","author":"Tharakaraman","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1542\/peds.99.1.93","article-title":"Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis","volume":"99","year":"1997","journal-title":"Pediatrics"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/s41467-017-01858-w","article-title":"Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein","volume":"8","author":"Tian","year":"2017","journal-title":"Nat. Commun."},{"key":"ref145","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","article-title":"The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide","volume":"147","author":"Tilmanis","year":"2017","journal-title":"Antiviral Res."},{"key":"ref146","article-title":"Safety and pharmacokinetics in healthy volunteers of the anti-RSV antiviral AK0529","volume-title":"1st international meeting on respiratory pathogens, September 3th, Singapore.","author":"Toovey","year":"2015"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref148","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/jac\/dkp421","article-title":"DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis","volume":"65","author":"Triana-Baltzer","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref149","doi-asserted-by":"publisher","first-page":"e7788","DOI":"10.1371\/journal.pone.0007838","article-title":"Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein","volume":"4","author":"Triana-Baltzer","year":"2009","journal-title":"PLoS One"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jac\/dkq387","article-title":"Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181","volume":"66","author":"Triana-Baltzer","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref151","first-page":"77","article-title":"S-033188, a small molecule inhibitor of cap-dependent endonuclease of influenza A and B virus, leads to rapid and profund viral load reduction","volume-title":"Options for the control of influenza IX","author":"Uehara","year":"2016"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pharmthera.2016.06.012","article-title":"Nanobodies\u00ae as inhaled biotherapeutics for lung diseases","volume":"169","author":"Van Heeke","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref153","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nsmb.1707","article-title":"Solution structure and functional analysis of the influenza B proton channel","volume":"16","author":"Wang","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref154","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/1744666X.2017.1389647","article-title":"RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations","volume":"13","author":"Wasserman","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref155","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nature12392","article-title":"Characterization of H7N9 influenza A viruses isolated from humans","volume":"501","author":"Watanabe","year":"2013","journal-title":"Nature"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tvjl.2016.12.020","article-title":"Middle East respiratory syndrome (MERS) coronavirus and dromedaries","volume":"220","author":"Wernery","year":"2017","journal-title":"Vet. J."},{"key":"ref157","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.onehlt.2016.12.001","article-title":"MERS-coronavirus: from discovery to intervention","volume":"3","author":"Widagdo","year":"2017","journal-title":"One Health"},{"key":"ref158","article-title":"Position paper on collection and use of convalescent plasma or serum as an element in Middle East Respiratory Syndrome Coronavirus response","year":"2014"},{"key":"ref159","article-title":"Influenza In Focus: Up to 650000 people die of respiratory diseases linked to seasonal flu each year","year":"2017"},{"key":"ref161","article-title":"Clinical mamagment of severe acute respiratory infection when MESR-CoV infection is suspected: interim guidance","year":"2019"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijid.2015.10.009","article-title":"Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma","volume":"41","author":"Wu","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref163","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","article-title":"Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract","volume":"368","author":"Wu","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref164","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.antiviral.2003.07.002","article-title":"Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection","volume":"60","author":"Wyde","year":"2003","journal-title":"Antiviral Res."},{"key":"ref165","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.antiviral.2005.06.009","article-title":"Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol","volume":"178","author":"Wyde","year":"2005","journal-title":"Antiviral Res."},{"key":"ref166","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00431-018-03310-7","article-title":"New therapies for acute RSV infections: where are we?","volume":"68","author":"Xing","year":"2019","journal-title":"Eur. J. Pediatr."},{"key":"ref167","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fimmu.2018.01547","article-title":"Advancements in host-based interventions for influenza treatment","volume":"9","author":"Yip","year":"2018","journal-title":"Front. Immunol."},{"key":"ref168","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.antiviral.2015.09.008","article-title":"Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults","volume":"123","author":"Zenilman","year":"2015","journal-title":"Antiviral Res."},{"key":"ref169","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1128\/JVI.00446-15","article-title":"Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection","volume":"89","author":"Zhao","year":"2015","journal-title":"J. Virol."},{"key":"ref170","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab","volume":"203","author":"Zhu","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref171","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bmcl.2017.11.029","article-title":"Isosteric ribavirin analogues: synthesis and antiviral activities","volume":"28","author":"Zhurilo","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref172","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1542\/peds.2009-2092","article-title":"Bronchiolitis: recent evidence on diagnosis and management","volume":"125","author":"Zorc","year":"2010","journal-title":"Pediatrics"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses \u2013 drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref174","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","volume":"386","author":"Zumla","year":"2015","journal-title":"Lancet"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.01327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T16:13:08Z","timestamp":1609949588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2019.01327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":173,"alternative-id":["10.3389\/fmicb.2019.01327"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2019.01327","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"article-number":"1327"}}